Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Philip Morris International Inc. (PM) vs Revvity Inc (RVTY) Price & Performance

Philip Morris International Inc.Trade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Philip Morris International Inc. vs Revvity Inc — how do they compare? Philip Morris International Inc. trades at $200.2 (market cap $312.50B), while Revvity Inc trades at $152.05 (market cap $16.98B). The key difference: Philip Morris International Inc. is far larger — about 18.4× Revvity Inc's market cap, and Philip Morris International Inc. pays the higher dividend (3.19%). Which is the better fit depends on your goals — on Pluang, investors hold Philip Morris International Inc. for 85 Days and Revvity Inc for 12 Days on average.

PMRVTY
Market Cap
$312.50B$16.98B
Volume
5,517,1721,456,900
Sector
Consumer StaplesHealth
52-Week High
$200.50$157.36
52-Week Low
$144.33$82.26
Typical Hold Time
85 Days12 Days
Enterprise Value
$355.62B$19.30B
Dividend Yield
3.19%0.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Philip Morris International Inc.

Philip Morris International (PM) trades at $200.5, up 5.3% over 24 hours, with a bullish technical signal and strong earnings beats in Q1 and Q2 2026. The company shows robust fundamentals with 2025 revenue of $40.65B and net income of $11.35B, supported by a 67.48% gross margin. Recent news highlights expansion of smoke-free products like ZYN and IQOS, now over 40% of revenue, driving growth amid industry shifts.

Outlook is positive with analyst consensus at Buy (68%) and a $212.17 price target, though elevated P/E of 26.46 and regulatory risks in tobacco remain concerns. Earnings growth and smoke-free product adoption are key catalysts, but investors should monitor debt levels and competitive pressures.

Revvity Inc

RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).

The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

PM
10% Buy90% Sell
Avg holding period · 85 Days
RVTY

No sentiment data available yet.

Top news

Latest headlines on both assets

About Philip Morris International Inc.

Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.

Read more on PM →

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY →